These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23512383)

  • 1. Effective long-term treatment of Cushing's disease with pasireotide: a case report.
    Lu L; Duan L; Jin Z; Lu Z; Gu F
    Endocr Pract; 2013; 19(4):e92-6. PubMed ID: 23512383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-month phase 3 study of pasireotide in Cushing's disease.
    Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
    N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
    Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
    Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
    Pedroncelli AM
    Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
    Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
    J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pasireotide: a review of its use in Cushing's disease.
    McKeage K
    Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
    Boscaro M; Bertherat J; Findling J; Fleseriu M; Atkinson AB; Petersenn S; Schopohl J; Snyder P; Hughes G; Trovato A; Hu K; Maldonado M; Biller BM
    Pituitary; 2014 Aug; 17(4):320-6. PubMed ID: 23943009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.
    Lacroix A; Gu F; Schopohl J; Kandra A; Pedroncelli AM; Jin L; Pivonello R
    Pituitary; 2020 Jun; 23(3):203-211. PubMed ID: 31875276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.
    Shimon I; Rot L; Inbar E
    Pituitary; 2012 Dec; 15(4):608-13. PubMed ID: 22918543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
    Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
    Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.
    Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Boscaro M; Arnaldi G
    Pituitary; 2015 Jun; 18(3):359-65. PubMed ID: 24952218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.
    Samson SL
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):445-50. PubMed ID: 25003365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
    Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
    Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
    MacKenzie Feder J; Bourdeau I; Vallette S; Beauregard H; Ste-Marie LG; Lacroix A
    Pituitary; 2014 Dec; 17(6):519-29. PubMed ID: 24287689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
    Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
    Findling JW; Fleseriu M; Newell-Price J; Petersenn S; Pivonello R; Kandra A; Pedroncelli AM; Biller BM
    Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.
    Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R
    Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
    Lau D; Rutledge C; Aghi MK
    Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
    Pivonello R; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Trovato A; Hughes G; Salgado LR; Lacroix A; Schopohl J; Biller BM;
    Clin Endocrinol (Oxf); 2014 Sep; 81(3):408-17. PubMed ID: 24533697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
    Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Polenta B; Spinello M; Boscaro M; Arnaldi G
    Pituitary; 2015 Feb; 18(1):60-7. PubMed ID: 24482099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.